The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
The trial that in 2005 set out to establish the comparative safety of celecoxib, ibuprofen and naproxen has been delivered with a bang.
Dr. Jack Cush: Pregnancy Infections with TNF Blockers (abstract 2049)
Dr. Jack Cush discusses abstract 2049 (http://acrabstracts.org/abstract/serious-infections-in-ra-offspring-exp…), as presented at the 2016 ACR/ARHP Annual Meeting.
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.The Cyclophosphamide Or Transplantation (SCOT) multicenter trial was designed to evaluate for long term benefit of myeloablative autologous HSCT over CYC.
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
Dr. Jack Cush: Interview with Alex Azar, president, Eli Lilly & Co.
Dr. Jack Cush interviews Alex Azar, president, Eli Lilly & Co at the 2016 ACR/ARHP Annual Meeting.
Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Dr. Arthur Kavanaugh: The Great Debate
Dr. Arthur Kavanaugh discusses The Great Debate on discontinuing and tapering biologic therapies for patients in low-disease activity or remission, which he co-presented with Dr. Paul Emery at the 2016 ACR/ARHP Annual Meeting.
Dr. Arthur Lau: FRAME Study
Dr. Lau updates us on the osteoporosis FRAME study presented at the 2016 ACR/ARHP Annual Meeting.
Dr. Chad Deal: 2015 Workforce Study
Dr. Chad Deal, a rheumatologist with the Cleveland Clinic, discusses the 2015 ACR WorkForce Study as presented at the 2016 ACR/ARHP Annual Meeting.
Dr. Tajvur Saber: Why RheumNow is "Brilliant"
Dr. Tajvur Saber, a rheumatologist in Pakistan, discusses why she thinks RheumNow is brilliant.
Dr. Len Calabrese: New IL-6 therapies, JAK space, and infection complications
Dr. Len Calabrese reviews what sessions he is most interested in at the 2016 ACR/ARHP Annual Meeting.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
In the past, the randomized controlled prospective MAINRISTAN trial demonstrated superiority of rituxan (RTX) over azathioprine for maintenance of remission at 22 months in patients with ANCA-associated vasculitis after CYC remission induction.
The potential association of herpes zoster with giant cell arteritis (GCA) has been a debated topic and certainly has gotten some attention at ACR 2016 this year.
Education on MACRA is the key to successful survival. The important take home points noted in Dr. Will Harvey’s lecture at ACR 2016 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs) are stated below.
